Publication at First Faculty of Medicine |
2023
Abstract
Several different types of systemic therapy are available for the treatment of metastatic castration-resistant prostate cancer. The more lines of therapy are used, the more patients' lives can be prolonged.
However, despite receiving treatment, patients gradually develop disease progression. Therefore, other treatment modalities are being sought that would prolong the survival of patients with metastatic castration-resistant prostate cancer.
PARP (poly(ADP-ribose)polymerase) inhibitors have been shown to be effective in these patients both in monotherapy and in combination with ARTA therapy. The most recent data have been available for the olaparib PARP inhibitor.